A mid-sized, global pharmaceutical company is seeking novel formulation approaches and technologies that enable drug delivery for sustained periods. Specifically, the team is interested in approaches that allow for once weekly dosing from oral and transdermal delivered drugs, and long-acting injectable platforms (intravenous, intramuscular, and subcutaneous) that allow for a 4–6-month dosing regimen.
Approaches of Interest:
- Approaches should work with small molecule drug compounds
- Open to a wide range of formulation and drug delivery approaches for the delivery routes of interest, including, but not limited to, nanoparticles, gastro-retentive gels, transdermal patches, and implants
- Solutions that include information on ease of manufacture, regulatory requirements, and safety data will be prioritized
- Approaches that have been developed for specific indications are in scope if the platform can be applied to multiple disease areas and drug compounds
Out of Scope:
- Approaches that cannot be applied to small molecules
- Active drug delivery devices, such as pumps
Developmental Stages of Interest:
- Opportunities from preclinical stage onwards that have pharmacokinetic validation with a model compound are in scope
- Opportunities with in vivo data will be given priority
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Appropriate solutions will lead to a funded research and/or manufacturing collaboration of 1-2 years, with potential outcomes leading to licensing of assets, and investment. For earlier stage projects, research funding or PhD studentships may be available.
Access full details
See the full details and submit your response through Inpart Connect.
